Caption Management, LLC Editas Medicine, Inc. Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $317,500 - $564,388	50,800 New	50,800 $514,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $999,000 - $2.14 Million	100,000 New	100,000 $1.18 Million
Q4 2021 Feb 11, 2022	SELL	$26.55 - $40.57 $1.45 Million - $2.22 Million	-54,600 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $11.2 Million - $20.8 Million	-284,900 Reduced 83.92%	54,600 $2.24 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $2.8 Million - $5.07 Million	89,500 Added 35.8%	339,500 $19.2 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $8.54 Million - $19.5 Million	215,000 Added 614.29%	250,000 $10.5 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $203,025 - $632,625	7,500 Added 27.27%	35,000 $2.45 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $771,650 - $1.02 Million	27,500 New	27,500 $771,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $2.14 Million - $3.98 Million	-115,800 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $1.72 Million - $3.8 Million	115,800 New	115,800 $2.3 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $154M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.